Heparin Market to Gain a Revenue Worth US$16.3 Billion by 2024

The global heparin market is anticipated to attract growth opportunities on the back of the rising count of surgical procedures and increasing treatment of venous thromboembolism including pulmonary embolism and deep vein thrombosis.

Global Heparin Market: Snapshot

The global heparin market is anticipated to attract growth opportunities on the back of the rising count of surgical procedures and increasing treatment of venous thromboembolism (VTE) including pulmonary embolism (PE) and deep vein thrombosis (DVT). Anticoagulant heparin holds the ability to reduce blood clotting. It could be used in blood transfusion, blood samplings during prophylaxis treatment, and the treatment of blood clotting disorders.

As per the analysis of the report, the global heparin market could expand at a CAGR of 6.2% for the forecast period 2017–2025 to reach a valuation of US$16.3 bn by the end of 2025. In 2017, the market attained a valuation of US$10.1 bn.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=803

LMWH Wins by Share, ULMWH Impresses by Novelty

As studied by the analysts, the world heparin market could be segmented on the basis of product, source, and formulation. By product, the market is predicted to encompass three segments, viz. unfractionated heparin (UFH), low molecular weight heparin (LMWH) and ultra-low molecular weight heparin (ULMWH). Amongst these products, LMWH had accounted for a king’s share in the recent past and is a widely used heparin to this date.

Generic and biosimilar drug manufacturers are expected to be empowered with growth opportunities birthing from the patent expiration of a majority of LMWHs. Since LMWH does not cross the placenta, it has been recommended as one of the most appropriate forms of heparin to be used during pregnancy by the Royal College of Obstetrics and Gynecology (RCOG) and National Institute for Health and Care Excellence (NICE). However, ULMWH is still used as a more novel therapeutic among the products in the heparin family.

As per a segmentation by source, the world heparin market is prognosticated to be classified into bovine and porcine. After its ban in the U.S. and Europe in the 90’s, bovine-sourced heparin had been proposed by the Center for Drug Evaluation and Research (CDER) to be reintroduced in the U.S. By formulation, the market could be divided into oral and parenteral.

Request For Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=803

Long-term DVT/PE Complications Catapult North America

In terms of regional segmentation, the international heparin market is envisaged to witness the dominance of North America followed by Europe in the coming years. By the completion of the forecast timeframe, North America could be leading the market with a US$6.0 bn secured under its belt. An estimate one-third of the DVT/PE patients in the U.S. could have a recurrence within 10 years and nearly half of them could develop long-term complications. Increasing incidences of coagulation disorders and burgeoning geriatric population are prophesied to help the Europe market to achieve a handsome growth in the near future.

Not to forget, Asia Pacific could be a faster growing region of the international heparin market rising at a 7.6% CAGR due to its largely untapped nature. The probability of PE in India, according to the National Institute of Health Consensus, is close to a 20.0%, whereas the overall incidence of DVT after elective hip surgery is approximately a 45.0% to 70.0%. The Middle East and Africa and Latin America are foreseen to tread upon the heels of Asia Pacific.

Request for Discount on this Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=803

Some of the prominent companies operating in the worldwide heparin market could include Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Fresenius SE & Co. KGaA, Sanofi, Pfizer, Inc., LEO Pharma A/S, Aspen, Baxter International Inc., B. Braun Melsungen AG, and Syntex S.A.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.”

Contact
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/